Polysulfone Membrane and Molding Resins Patents: Leaders & Trends 2026
- 22.8% sits with five filers. Top 5 assignees hold 646 of 2,834 records in scope — dense but not closed to new entrants.
- Filing cooled after 2020's peak. 195 records in the peak year gave way to a -38% drop from 2021 (144) to 2024 (90), the last complete year.
- Separation and polymer composition dominate. B01D and C08L classes cover 30.6% and 24.6% of records respectively, far ahead of sterilising-specific A61L at 5.6%.
Filing growth compares 2021 (144 records) with 2024 (90) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,834 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 2,834 published records filed between 2015 and mid-2026 that combine polysulfone, polyethersulfone or polyphenylsulfone resin chemistry with a functional claim — hydrolysis resistance, steam sterilization, transparent molding, phase inversion, notched impact performance or solvent casting. That pairing matters: it separates resin-grade chemistry claims from generic polymer filings and points the corpus at the two end markets that actually drive this material family, filtration membranes and sterilizable molded parts.
Because publication lags filing by roughly 18 months, the 2025 and 2026 counts in any trend view are still filling in and should not be read as a real slowdown yet. The complete-year comparison from 2021 to 2024 is the more reliable signal of where filing activity is actually heading.
Filing trend and technology composition
Two views of the same 2,834 records: how filing volume has moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017–2026
Filings rose from 93 in 2017 to a peak of 195 in 2020, then eased to 90 by 2024 — a -38% move from 2021's 144 filings over that three-year span. Treat 2025 and 2026 as undercounted rather than as evidence of further decline.
Technology composition by IPC subclass
Separation processes (B01D) and polymer compositions (C08L) lead at 30.6% and 24.6% of the 2,834 records respectively; additive use (C08K), condensation polymers (C08G) and polymer processing (C08J) each sit at 13.5%, with shaping (B29C) at 7.6%, battery/fuel-cell use (H01M) at 6.5% and sterilising applications (A61L) at 5.6%. Because records carry multiple classes, these shares add up to more than 100% of the record total.
Shares are the percentage of the 2,834 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Polysulfone Membrane and Molding Resins with Eureka
This page is one run against one query. Ask Eureka your own question about polysulfone membrane and molding resins and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
US11578208B2 — Aromatic polysulfone resin and membrane thereof
An aromatic polysulfone resin having a repeating unit represented by Formula (I) and a repeating unit represented by Formula (II), where the molar ratio (m:n) of Formula (I) to Formula (II) content is 1:2,000 to 1:200, with phenylene hydrogens in either formula optionally substituted by an alkyl group, an aryl group or a halogen atom.Filed by Sumitomo Chemical Company, granted 2023-02-14.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US10076340B2 | Surgical tool system with a tool unit that includes a power generating unit and a battery and control module … | 795 |
| 2 | US20100210745A1 | Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, a… | 718 |
| 3 | US20200197027A1 | Surgical Systems With Twist-Lock Battery Connection | 613 |
| 4 | US20180372806A1 | System and method for determining an amount of degradation of a medical device battery | 466 |
| 5 | US20180368066A1 | System And Method For Providing Power From A Battery To A Medical Device | 441 |
| 6 | US5582615A | Handle for surgical clip applicator systems | 427 |
| 7 | US6248469B1 | Composite solid polymer electrolyte membranes | 408 |
| 8 | US4164794A | Prosthetic devices having coatings of selected porous bioengineering thermoplastics | 388 |
| 9 | US7550216B2 | Composite solid polymer electrolyte membranes | 367 |
| 10 | US20100233146A1 | Coatings and Surface Treatments Having Active Enzymes and Peptides | 317 |
Citation counts favour older filings that have had more time to accumulate references — read them as a signal of influence within this searched set, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about this field
Four read-throughs from the filing trend, the technology mix and the assignee ranking, aimed at the decisions R&D and IP teams actually need to make.
The top is dense, not closed
Five assignees hold 646 of the 2,834 records in scope, and the top ten extend that to 944 records (33.3%). That leaves roughly two-thirds of filings spread across a long tail of single- and few-filing entrants — concentrated enough to require freedom-to-operate checks, not so concentrated that new claims are shut out.
Filtration outweighs sterilisation claims by a wide margin
Separation-process claims (B01D) appear in 30.6% of records against sterilising-specific claims (A61L) at 5.6%. Most steam-sterilization and hydrolysis-resistance language in this corpus is being claimed as a membrane or molded-part property rather than as a standalone sterilising method, which shapes how a new filing should be classified and searched.
Volume has pulled back from its 2020 peak
Filings peaked at 195 in 2020 and the last complete comparison year, 2024, sits at 90 — a -38% move from 2021's 144. Recent-year assignee momentum is mixed rather than uniformly down: some established filers show zero activity in the latest year while at least one shows a doubling, so the pullback is not evenly distributed.
US and EPO carry the bulk of filing activity
The United States (882) and European Patent Office (748) are the largest receiving offices, with WIPO/PCT filings (217) and Germany (137) trailing well behind. Canada (132) and Australia (129) round out the set, suggesting protection strategies concentrate on the two largest end markets before extending elsewhere.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to polysulfone membrane and molding resins, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders span membrane filtration, medical device and specialty resin businesses, with a long tail of smaller filers behind them. Co-assignee pairs are rare in this dataset — ten pairs total — which points to mostly internally-developed claims rather than joint filings.
A filtration-and-medical-device leader sets the pace
The top-ranked assignee holds 220 records, well ahead of the fifth-place filer at 76 and tenth place at 52 — a steep drop-off that marks this as a leader-plus-tail structure rather than an even spread among a handful of majors.
Joint filing is the exception, not the rule
Only ten co-assignee pairs appear across the corpus, the strongest linking two related entities within the same corporate group. Most records in this dataset carry a single assignee, consistent with resin chemistry and membrane formulation being developed in-house rather than through joint ventures.
Latest-year activity is uneven across established filers
Some ranked assignees show a single-digit filing with a sharp percentage swing in the latest year, while several long-standing filers show zero recent activity. Given the 18-month publication lag, a zero in the latest year is not conclusive evidence a filer has stopped — it may simply not have published yet.
| Assignee | Recent year | YoY |
|---|---|---|
| Stryker Corporation | 2 | +100% |
| Agfa-Gevaert NV | 1 | -75% |
| Pall Corporation | 0 | — |
| Toray Industries, Inc. | 0 | — |
| Solvay Specialty Polymers USA, LLC | 0 | -100% |
| Mitsubishi Gas Chemical Company, Inc. | 0 | — |
| Solvay Advanced Polymers, LLC | 0 | — |
| Teijin Limited | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, whitespace filing, or tracking a named competitor.
Run a freedom-to-operate check against the top 10
With 33.3% of records held by ten assignees, a targeted FTO search against those portfolios before filing in B01D or C08L is more efficient than screening the full 2,834-record set.
Start an FTO searchTrack momentum shifts in real time
Recent-year activity is mixed across the ranked leaders; a standing alert on the leading assignees' latest publications will catch a resumption faster than a static report.
Set up assignee trackingScope a claim in the under-claimed branches
Fuel-cell membrane overlaps and transparent-molding grades show thinner coverage than the core filtration and composition classes — worth a dedicated novelty search before drafting.
Explore white spaceCommon questions about this landscape
The ranking covers 100 companies, with the leading assignee holding 220 of the 2,834 records in scope. The gap to the field is steep: fifth place holds 76 records and tenth place holds 52, so the top five together account for 22.8% of all records while the top ten reach 33.3%. That leaves a long tail of assignees with only a handful of filings each, meaning the field is concentrated at the top but still has substantial room for new entrants outside the leading group.
Filing peaked at 195 records in 2020 and had fallen to 90 by 2024, a -38% move from 2021's 144 filings over that three-year span. That is the most reliable read because 2024 is the last year with largely complete publication data. Figures for 2025 and 2026 are still incomplete due to the roughly 18-month lag between filing and publication, so they should not yet be read as confirmation of a continued decline.
Separation processes under IPC class B01D appear in 30.6% of the 2,834 records, making membrane and filtration applications the single largest claim area. Polymer composition claims (C08L) follow at 24.6%, with additive use, condensation polymer chemistry and polymer processing each around 13.5%. Sterilising-specific claims (A61L) are comparatively rare at 5.6%, which suggests most hydrolysis-resistance and steam-sterilization language is being claimed through membrane or molding property claims rather than as standalone sterilising methods.
US11578208B2, assigned to Sumitomo Chemical Company, claims an aromatic polysulfone resin built from two repeating units in a specific molar ratio range of 1:2,000 to 1:200, with defined substitution options on the phenylene hydrogens. It is a composition-of-matter claim rather than a process or application claim, so it constrains resin formulations that fall inside that stoichiometric window regardless of what the resin is ultimately used for. Anyone drafting a new polysulfone resin composition claim should check their monomer ratio and substitution pattern against this range before finalising claim language.
The technology composition data shows the densest claim activity sits in separation processes and general polymer composition, while adjacent branches such as fuel-cell membrane applications, solvent-casting process parameters, and transparent molding grades for medical housings carry comparatively thin coverage. These branches sit next to well-covered core claims rather than in an entirely unclaimed area, so a workable strategy is to file narrowly around a specific processing parameter or end-use combination rather than attempting a broad composition claim, which is more likely to collide with the concentrated top-ten portfolios.
Research Polysulfone Membrane and Molding Resins in depth with Eureka
Go past this page: query the whole polysulfone membrane and molding resins corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.